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Objective.Toevaluateifnewimiquimodformulationsusingashortertreatmentdurationaresafeandeﬃcacioustotreatanogenital
warts. Methods. In two studies 534 women ≥12 years of age (mean 33.4) with 2–30 warts (mean 7.9) and total wart area ≥ 10mm2
(mean 166.3) were randomized (1:2:2) to placebo (106), imiquimod 2.5% (212) or 3.75% (216) creams applied once daily until
complete clearance or a maximum of 8 weeks. Results. For placebo, imiquimod 2.5% and 3.75%, respectively, complete clearance
of all warts was achieved in 14.2%, 28.3%, and 36.6% of women (intent-to-treat, P = 0.008 imiquimod 2.5%, and P<0.001
3.75% versus placebo). Mean changes in wart counts were −10.7%, −50.9%, and −63.5% (per-protocol, P<0.001 each active
versus placebo) and safety-related discontinuation rates 0.9%, 1.4%, and 2.3%. Conclusions. Imiquimod 3.75% applied daily for
up to 8 weeks was well tolerated and superior to placebo in treating women with external anogenital warts.
1.Introduction
Humanpapillomavirus(HPV)infectionisthemostfrequent
sexually transmitted disease in the United States [1]. The
major clinical focus in women with HPV has been on the
prevention of cervical cancer, predominantly associated with
oncogenic HPV types such as 16 and 18, through screening,
and, more recently, through HPV vaccination [2]. External
(ano)genital warts (EGW), however, are also a common
manifestation of HPV infection, usually associated with
HPV types 6 and 11, types not included in one of the two
marketed vaccines [3]. EGWs are frequently multicentric
and recurrent. The estimated prevalence of EGWs in the
sexually active population between 15 and 49 years of age in
the United States is 1% [4]. Up to 7.2% of women report
a history of EGWs [5]. A signiﬁcant detrimental impact2 Infectious Diseases in Obstetrics and Gynecology
on quality of life was observed in adults with a current
diagnosis of EGWs, particularly in young women [6]. In
a study assessing the psychosocial burden of HPV-related
disease, women with EGWs reported lower general quality
of life scores than women with abnormal Papanicolaou
smears or biopsy-proven cervical intraepithelial neoplasia
[7]. With an HPV-speciﬁc impact proﬁle instrument, the
impact on quality of life of having EGWs was second to that
of having cervical intraepithelial neoplasia 2/3 [7]. EGWs
also represent a signiﬁcant burden to the health care system
with an estimated 385,000 initial visits to physician oﬃces
in 2008 [8] and $200 million in direct costs annually in the
United States [9].
Treatments for EGWs focus on the removal of visible
warts [3] and can be divided broadly into two categories:
provider-administered ablative/cytodestructive therapies
(including cryotherapy, laser ablation, and trichloroacetic
acid) and patient-administered topical therapies (such
as podophyllotoxin, sinecatechins, and imiquimod) [10].
Imiquimod directly activates innate immune cells through
Toll-like receptor 7, resulting in production of cytokines
[11]. Indirectly, imiquimod enhances antigen-speciﬁc
cell-mediated immunity [11]. Imiquimod 5% cream was
approved in 1997 to treat EGWs using a regimen of
application to warts 3 times per week (3x/week) until
complete clearance of baseline/target warts in the designated
anogenital area(s) or for a maximum of 16 weeks of
treatment [12]. Long treatment durations are one of
the impediments to treatment adherence [13–15]. While
increasing the dosing frequency might be considered to
shorten the treatment duration with imiquimod, application
of imiquimod 5% more frequently than 3x/week resulted
in a greater incidence and severity of local adverse events,
without an improvement in eﬃcacy [16–18].
Formulations with lower concentrations of imiquimod
were developed to potentially allow for a decrease in treat-
ment duration by using daily dosing. Two identical placebo-
controlled phase 3 studies have been recently completed
evaluating the safety and eﬃcacy of imiquimod 2.5% and
3.75% cream applied once daily for up to a maximum of 8
weeks to treat EGWs in women and men [19]. As gender
stratiﬁcation in randomization was included in the design
of the studies, and the safety and eﬃcacy outcomes diﬀered
b e t w e e nw o m e na n dm e n[ 19], we herein report the results
fromthewomenenrolledinthestudies;theresultsfrommen
will be reported separately.
2. Methods
2.1. Study Population. Women participating in the studies
were 12 years or older, in general good health, with 2 to 30
EGWs in the vulvar (including mons), inguinal, perineum,
and/or perianal areas, and with a minimum total wart area
of 10mm2. EGWs were diagnosed clinically; to mimic real
world practice, histologic conﬁrmation was not required.
Exclusions included known human immunodeﬁciency virus
infection, immunosuppression, other genital infections,
allergy to imiquimod or cream excipients, history of high-
risk type HPV infection, high-grade pathology on Papani-
colaou smear, pregnancy, or lactation. Additional exclusions
included imiquimod or HPV vaccination within 1 year, and
sinecatechins within 12 weeks, cytotoxics, immunomodula-
tors/immunosuppressives,systemicantivirals(excludingoral
antiherpes agents and oseltamivir), investigational therapies,
and any treatments procedures within the anogenital area
within4weeks.Womenagreedtorefrainfromsexualactivity
while the study drug was on their skin. Women also agreed
to use adequate contraception during the study.
The studies were conducted in compliance with Good
Clinical Practice guidelines and approved by a central
institutional review board; at some study centers, approval
was also obtained from a local institutional review board. All
participants provided written informed consent. For women
<18 years of age, consent was obtained from the parent
or legal guardian and assent from the minor. Enrollment
began in June 2008, and all study procedures were completed
by June 2009. Each of the two studies was registered at
www.clinicaltrials.gov (NCT00674739 and NCT00735462).
2.2. Study Designs and Study Drug Dosing. Women were
enrolled at 70 study centers in the United States. Each study
center participated in only one of the two studies. Each study
included a screening visit, an evaluation phase (treatment
period of up to 8 weeks and a no-treatment period of up
to 8 weeks) of up to 16 weeks, and an observational follow-
up phase of up to 12 additional weeks in women with
complete clearance. A no-treatment period was included to
allow adequate resolution of local skin reactions (LSRs) or
application site reactions (ASRs) that might interfere with
wart assessments as well as to determine if residual warts
would resolve without further treatment. An observational
follow-up phase of 12 weeks was included to assess sustained
complete clearance in those women who achieved initial
complete clearance.
Identically appearing study kits were prepackaged for
each study center according to a computer-generated ran-
domization schedule using a 1:1:2 allocation for placebo,
imiquimod2.5%,andimiquimod3.75%cream(3MHealth-
care, Loughborough, UK) and a block size of 5. Eligible
women were randomized at each study center by assigning
them to study kits in sequential order. The treatment assign-
ment was concealed from the participant, the investigators
and their staﬀ, and the clinical research team.
Participants were instructed to self-apply up to one
packet (250mg cream) of study drug once daily to warts
identiﬁed at baseline as well as to any new warts that
developed during the treatment period. A thin layer of the
cream was applied to cover each wart area, prior to normal
sleeping hours, and removed approximately 8 hours later by
washing. Women were told not to apply study cream to the
urethra, vagina, or cervix. Internal warts, for example, vagi-
nal or cervical, were neither treated nor counted as EGWs.
Temporary dosing interruptions (rest periods) were allowed
to manage an LSR or an adverse event (AE); treatment was
resumed upon adequate resolution. Missed doses were not
to be made up, and the maximum duration of treatment was
8 weeks (including rest periods). Participants were assessed
every 2 weeks during the evaluation phase. Participants withInfectious Diseases in Obstetrics and Gynecology 3
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515
Imiquimod 3.75%
216
Completed
78 (73.6%)
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142 (67%)
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Placebo
106
Imiquimod 2.5%
212
Completed
162 (75%)
Discontinued: 28 (26.4%)
Adverse event: 1 (0.9%)
Lost to follow-up: 16 (15.1%)
Other: 11 (10.4%)
Discontinued: 70 (33.0%)
Adverse event: 3 (1.4%)
Lost to follow-up: 43 (20.3%)
Other: 24 (11.3%)
Discontinued: 54 (25.0%)
Adverse event: 5 (2.3%)
32 (14.8%)
17 (7.9%) Other:
Lost to follow-up:
Figure 1: Disposition of women in the studies, combined, evaluation phase. Percents displayed are percent of women randomized by
treatment group. Adverse events category includes women discontinuing for local skin reactions.
complete clearance of all warts within all anogenital areas
entered the 12-week observational follow-up period and
were assessed every 4 weeks or until they had a “recurrence”
of any wart (baseline or new) in any anogenital area.
2.3. Eﬃcacy Evaluation. The primary assessment was based
on the count of all EGWs (baseline and new, treated or
untreated) in all anogenital areas. A cluster of warts was
counted as a single wart. The primary eﬃcacy endpoint for
each study was the complete clearance rate, deﬁned as the
proportion of participants by the end of study (EOS) visit
with a zero count of EGWs in all of the anogenital anatomic
areas.Keysecondaryendpointsincludedthepartialclearance
rate (participants with ≥7 5 %r e d u c t i o ni nE G Wc o u n t ) ,
the change in wart counts from baseline, and the 12-
week sustained clearance rate. For each study, sample sizes
(combinedpopulationincludingbothgenders)wereselected
for placebo (90) and each active group (180) to have at
least a 90% power at a two-sided overall 5% level of
signiﬁcance,adjustingforanestimateddrop-outrateof20%,
to detect a diﬀerence in complete clearance rates of 30%
for the active groups versus 10% for the placebo group.
Replacement of participants was not allowed. The individual
s t u d i e sw e r en o tp r o s p e c t i v e l yp o w e r e df o ra n a l y s i sb y
gender. For intent-to-treat (ITT) analyses, imputations were
made for missing data points using last observation carried
forward. Complete clearance rates and partial clearance rates
were analyzed using Cochran-Mantel-Haenszel statistics,
stratifying by center, and for the overall population analyses,
by gender. Conﬁdence intervals were calculated using exact
binomial statistics. Pair-wise comparisons were performed
with Hochberg’s modiﬁed Bonferroni procedure [20]. The
percent change in wart count was analyzed using Analysis
of Covariance. Per-protocol (PP) analyses were performed
on a subset of participants who met predeﬁned criteria for
protocol compliance. All statistical analyses were performed
using SAS (Version 9.1.3, SAS Institute, Inc., Cary, NC).
2.4. Safety Evaluations. Hematology, serum chemistry, and
urinalysis tests were performed prestudy and at EOS.
For women of childbearing capacity, pregnancy tests were
performed at prestudy, treatment initiation, and every
4 weeks up to and including end of treatment (EOT).
Spontaneously reported AEs were collected at each visit
and graded as none, mild, moderate, and severe. AEs
were coded using the Medical Dictionary for Regulatory
Activities (Version 11.0). LSRs (erythema, edema, weep-
ing/exudate, ﬂaking/scaling/dryness, scabbing/crusting, and
erosion/ulceration) in the anogenital locations were also
assessed by the investigator at each visit. Each LSR was
graded as none, mild (not applicable to erosion/ulceration),
moderate or severe. LSRs were analyzed separately from
other AEs as they were collected systematically.
3. Results
3.1. Subject Population. In the two studies combined, 1049
women were screened, 534 were enrolled and 382 completed
the studies (Figure 1). Of the 515 women who were screen
failures, the most frequent reasons for exclusion were not4 Infectious Diseases in Obstetrics and Gynecology
Table 1: Demographic and external anogenital wart characteristics by treatment group, all women.
Women Placebo Imiquimod 2.5% Imiquimod 3.75% P value
106 212 216
Age, years
Mean (standard deviation) 32.9 (12.2) 32.8 (11.6) 34.2 (13.1) 0.462a
Median (range) 29 (18–75) 30 (17–78) 31 (15–81)
Race, n (%)
White 71 (67.0) 132 (62.3) 157 (72.7)
0.107b Black/African American 34 (32.1) 74 (34.9) 52 (24.1)
Other 1 (0.9) 6 (2.8) 7 (3.2)
Total wart area, mm2
Mean (standard deviation) 166.5 (303.0) 161.9 (362.1)c 170.6 (463.0) 0.975a
Median (range) 57 (6–1969)d 55 (10–4000)c 50 (10–5579)
Wart count, n
Mean (standard deviation) 8.3 (7.7) 7.9 (6.3)c 7.8 (6.1) 0.751a
Median (range) 5 (2–30) 6 (2–30)c 6 (2–30)
Duration since ﬁrst EGW diagnosis, years
Mean (standard deviation) 5.5 (8.3) 5.7 (7.8) 5.5 (8.1) 0.967a
Median (range) 1.4 (0.0–33.7) 2.1 (0.0–31.4) 1.6 (0.0–39.4)
First episode, n (%)
Yes 79 (74.5) 151 (71.2) 140 (64.8) 0.152b
Anatomical locations involved, n (%)
1 only 54 (50.9) 93 (43.9) 96 (44.4)
0.451b
2 or more 52 (49.1) 119 (56.1) 120 (55.6)
Vulvar 63 (59.4)e 138 (65.1)e 145 (67.1)e
Inguinal 10 (9.4)e 30 (14.2)e 28 (13.0)e
Perineal 51 (48.1)e 96 (45.3)e 109 (50.5)e
Perianal 48 (45.3)e 103 (48.6)e 97 (44.9)e
Perineal 51 (48.1)e 96 (45.3)e 109 (50.5)e
aP value from an ANOVA Ftest.
bP value from a Chi-square test.
cOne woman without wart data at baseline; wart count from screening used with no total area available.
dOne woman with wart area <10mm2.
eA woman may have more than one site involved, so total across anatomic sites may exceed 100%.
meeting the EGW diagnosis and wart count requirements
(272, 52.8%), “other” (93, 18.1%), and not willing to comply
with study requirements (49, 9.5%). The overall subject
noncompletion rate was 28.5% (152 women); approximately
60% of these women (91) were lost to follow-up. Discon-
tinuation rates were comparable across the three treatment
groups (Figure 1). Of the 143 women excluded from the PP
analysis, 138 were excluded for “treatment noncompliance,”
most because they were lost to follow-up early in the study
and did not meet the minimum criteria for treatment
exposure.
Study participant characteristics by treatment group are
presented in Table 1. The mean age was 33.4 years; only
three women were <18 years of age. Overall, 67.4% of the
women were white, the mean baseline wart count was 8.7,
and the mean total wart area was 166.3mm2. More than
two-thirds (69.3%) of the women reported that the current
episode of EGW was their ﬁrst. The majority of women
(54.5%) had warts on 2 or more anogenital locations; the
most frequently involved locations were vulvar (64.8%) and
perineal (47.9%). The duration since EGW diagnosis for the
overall population was 5.6 years. There were no statistically
signiﬁcant diﬀerences among the treatment groups with
regard to the baseline characteristics examined (Table 1).
3.2.Eﬃcacy. Fortheprimaryendpointofcompleteclearance
of all warts (baseline and new) at EOS, in the combined
analyses in women, both imiquimod groups were superior to
placebo (Figures 2(a),I T T ,a n d2(b), PP). In the individual
studies, only imiquimod 3.75% was statistically superior to
placebo in women in both of the studies (34.0% versus
16.0%,ITT, P = 0.017;38.8%versus12.5%,ITT,P<0.001).
Imiquimod 2.5% was only superior to placebo in one study.
For the women who achieved complete clearance in the
combined analyses, median time to clearance was 71.0, 60.0,
and 57.0 days for placebo, imiquimod 2.5%, and 3.75%,Infectious Diseases in Obstetrics and Gynecology 5
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Figure 2: Complete clearance rates. (a) Intent to treat (b) per protocol. White: placebo, stippled: imiquimod 2.5%, solid black: imiquimod
3.75%. P-values from a Cochran-Mantel-Haenszel test, stratiﬁed by analysis site using two treatment groups at a time.∗indicates statistically
signiﬁcantforactiveversusplacebo,and †forimiquimod3.75%versus2.5%,usingHochberg’smodiﬁedBonferroniprocedure.Barsindicate
95% conﬁdence interval calculated using exact method.
respectively. For imiquimod 3.75%, complete clearance was
similar between women ≤35 versus >35 years, with one
versus multiple anatomical sites involved, or with ﬁrst
episode versus nonﬁrst episode disease. Complete clearance
rates (ITT) were numerically higher for those women who
were nonwhite (28/59, 47.5%) versus white (51/157, 32.5%),
had baseline wart counts ≤7 (54/133, 40.6%) versus >7
(25/83, 30.1%), had total wart area ≤150 (66/158, 41.8%)
versus >150mm2 (13/48, 27.1%), and had EGW diagnosis
duration ≤6 months (33/64, 51.6%) versus >6 months
to ≤24 months (17/55, 30.9%) and ≥24 months (29/97,
29.9%). In multivariate analyses, imiquimod 3.75% was
superiortoplaceboinwomenafteradjustmentsforage,race,
baseline wart count, baseline total area, ﬁrst versus nonﬁrst
episode, and EGW duration.
For the secondary endpoint of partial clearance (≥75%
reduction in wart count from baseline), imiquimod 3.75%
and 2.5% were superior to placebo (ITT and PP; Figure 3(a)
PP).Imiquimod3.75%wasalsosuperiortoimiquimod2.5%
by ITT (47.7% versus 36.3%, P = 0.015) but not PP. Simi-
larly, for change (percent) in wart count from baseline, both
of the imiquimod groups were superior to placebo (ITT and
PP; Figure 3(b), PP). Imiquimod 3.75% was also superior
to imiquimod 2.5% by ITT (mean −54.5% versus −40.1%,
P = 0.003). A signiﬁcant change in the wart count compared
to baseline was observed in the imiquimod 3.75% group as
early as week 2 (Figure 4, left axis).
For speciﬁc anatomic sites, imiquimod 3.75% cream was
superior to placebo with respect to complete clearance for
thevulvar(includingmons),perineal,andperianalareasand
was also superior to imiquimod 2.5% for the perianal area;
complete clearance was highest for the perianal area (78.5%,
Table 2, PP). Similarly, imiquimod 3.75% was superior to
placebo and 2.5% for these same areas, respectively, for
changeinwartcountcomparedtobaseline;themeanpercent
change was greatest for the perianal area (−82.2%, Table 2,
PP). Except for imiquimod 2.5% in the inguinal area, both
imiquimod groups had higher rates of clearance and greater
decreases in wart count numerically than placebo for all of
the anatomical areas. The lack of statistical signiﬁcance for
some of the subgroup comparisons may have been due to the
sample sizes.
In the women who achieved complete clearance and
entered the 12-week follow-up phase, complete clearance
was sustained in 9/9 (100.0%), 32/53 (60.4%), and 47/72
(65.3%) in the placebo, imiquimod 2.5%, and 3.75% groups,
respectively. A recurrence, deﬁned as any EGW in any of
the anogenital locations regardless if it was baseline or new,6 Infectious Diseases in Obstetrics and Gynecology
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Figure 3: Partial clearance rates and change in wart count from baseline. White: placebo, stippled: imiquimod 2.5%, solid black: imiquimod
3.75%. (a) Partial (≥75% reduction in wart count compared to baseline) clearance rates, PP. P values from a Cochran-Mantel-Haenszel
test, stratiﬁed by analysis site using two treatment groups at a time.∗indicates statistically signiﬁcant for active versus placebo, and †for
imiquimod 3.75% versus 2.5%, using Hochberg’s modiﬁed Bonferroni procedure. Bars indicate 95% conﬁdence interval calculated using
exact method. (b) Change in wart count compared with baseline, mean percent, PP. P values from an analysis of covariance test, controlling
for baseline wart count and analysis site.∗indicates statistically signiﬁcant for active versus placebo, and †for imiquimod 3.75% versus 2.5%,
using Hochberg’s modiﬁed Bonferroni procedure.
treatedoruntreated,wasobservedin0/9(0%),9/53(17.0%),
and 14/72 (19.4%) women, respectively. The rest of the
women were lost to follow-up.
3.3. Safety. The mean numbers of days treated were 50.5
(12.0), 43.2 (15.4), and 41.4 (16.3) days for the placebo,
imiquimod 2.5%, and 3.75% groups, respectively. About
40% of women in each treatment group experienced an AE
(Table 3). The proportions of women with any treatment-
related AE, or any ASR, were similar between the imiquimod
2.5% and 3.75% groups, but higher than in the placebo
group (Table 3). Nine women (1.7%) had AEs that led
them to discontinue study participation; of these, 6 (3
imiquimod 2.5%, and 3 imiquimod 3.75%) had AEs (all
ASRs) considered to be related to study cream. ASRs were
the AEs reported by the most women in the imiquimod
groups and were the only speciﬁc treatment-related AEs
reported by >1% of women overall (Table 3). The incidences
of the ASRs occurring in the most (application site pain,
application site irritation, and application site pruritus) were
generally comparable between imiquimod 2.5% and 3.75%
(Table 3).
There were 9 treatment-emergent serious AEs in 8
women;nonewasconsideredtoberelatedtostudycream.Of
these serious AEs, 2 resulted in women discontinuing study
participation; both were in the imiquimod 3.75% group
(pelvicmass/acuteabdomenandmalignantmelanoma).The
proportion of women requiring a rest period and the mean
missed doses for those who required a rest were similar for
imiquimod 2.5% and 3.75% (Table 3).
LSRs were frequent, with 69.6% and 76.8% of women
in the imiquimod 2.5% and 3.75% groups, respectively,
experiencing at least one LSR during the treatment phase
(Table 4). The mean LSR sum score (sum of the intensities
of all of the LSRs in a participant, maximum of 18) peaked
early and remained relatively ﬂat during treatment (Figure 4,
right axis). Erythema and ulceration were the severe LSRs
that occurred in the most women in each of the imiquimod
groups; rates were slightly higher in the imiquimod 3.75%
group versus the 2.5% group (Table 4).Infectious Diseases in Obstetrics and Gynecology 7
Table 2: Anatomic site-speciﬁc clearance rates, per protocol population.
Women Placebo Imiquimod 2.5% Imiquimod 3.75%
87 151 153
Anatomic site complete clearance, n/N a (%)
Vulvar 14/51 (27.5) 42/98 (42.9) 53/104 (51.0)b
Inguinal 2/9 (22.2) 4/18 (22.2) 9/20 (45.0)
Perineal 11/43 (25.6) 36/68 (52.9) 48/74 (64.9)b
Perianal 10/40 (25.0) 34/69 (49.3)b 51/65 (78.5)b,c
Change in wart count from baseline, mean percent (standard deviation)
Vulvar −23.8 (56.4) −52.3 (55.6)d −56.8 (75.8)d
Inguinal −27.2 (60.1) −14.4 (69.5) −49.3 (54.2)
Perineal −21.3 (62.5) −61.8 (46.1)d −74.6 (42.9)d
Perianal −11.6 (96.4) −52.7 (59.5)d −82.2 (40.4)d,e
a N is women with anatomic site involved.
bStatisticallysigniﬁcantversusplacebousingHochberg’smodiﬁedBonferroniprocedurewithP valuedeterminedbyCochran-Mantel-Haenszeltest,stratiﬁed
by analysis site two treatment groups at a time.
cStatistically signiﬁcant versus imiquimod 2.5% using Hochberg’s modiﬁed Bonferroni procedure with P value determined by Cochran-Mantel-Haenszel test,
stratiﬁed by analysis site two treatment groups at a time.
dStatistically signiﬁcant versus placebo using Hochberg’s modiﬁed Bonferroni procedure with P value determined by ANCOVA with main eﬀect treatment
and controlling for baseline lesion count and analysis site.
eStatistically signiﬁcant versus imiquimod 2.5% using Hochberg’s modiﬁed Bonferroni procedure with P value determined ANCOVA with main eﬀect
treatment and controlling for baseline lesion count and analysis site.
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Figure 4: Change in wart count compared with baseline (left axis,
circle, mean, ITT, last observation carried forward) versus local
skin reaction (LSR) sum score (right axis, square, mean, observed)
over time for imiquimod 3.75% during the evaluation phase.
M a x i m u mL S Rs u ms c o r e= 18. Shaded box indicates treatment
period of up to 8 weeks. P values were calculated using analysis
of covariance, controlling for baseline wart count, and analysis
site.∗indicates statistically signiﬁcant for active versus placebo, and
†for imiquimod 3.75% versus 2.5%, using Hochberg’s modiﬁed
Bonferroni procedure.
Clinical laboratory values, vital sign measurement and
physical examinations did not raise any signiﬁcant safety
concerns (data not shown). Of the 8 pregnancies that occu-
rred in the active groups, no abnormalities were reported in
3 infants; the other 5 women were lost to follow-up. There
were 3 pregnancies in the placebo group.
4. Discussion
In each of the individual studies, imiquimod 3.75% applied
daily for up to 8 weeks in women was superior (ITT) to
placebo with respect to the primary endpoint of complete
clearance all warts (baseline and new). These results were
consistentwiththoseforthecombinedmaleandfemalepop-
ulations in the individual studies, where imiquimod 3.75%
was also statistically superior to placebo in both studies [19].
In the combined analysis in women, imiquimod 3.75%
was also superior to placebo (ITT); the complete clear-
ance rate was higher for imiquimod 3.75% compared to
imiquimod 2.5% cream, although the diﬀerence was not
statistically signiﬁcant. For partial clearance and change in
wartcount,however,imiquimod3.75%wassuperiorto2.5%
(ITT). Interestingly, this incremental beneﬁt of imiquimod
3.75% versus 2.5% did not appear to be at the expense
of safety. Rates of severe LSRs were slightly higher in the
imiquimod 3.75% group, but overall tolerability was similar
to that of imiquimod 2.5%, including the proportions of
women with treatment-related AEs, who discontinued from
treatment, and who required rest periods. Comparisons
of safety, as well as overall safety conclusions, are limited
by sample size with respect to AEs of low frequency.
Qualitatively, however, the treatment-related AEs observed
were consistent with the known safety proﬁle for imiquimod
5% [21].
The combined complete clearance rates observed in
women (36.6% ITT and 43.1% PP for imiquimod 3.75%)8 Infectious Diseases in Obstetrics and Gynecology
Table 3: Summary of safety by treatment group, evaluation period, all women.
Women Placebo Imiquimod
2.5%
Imiquimod
3.75%
106 211a 217a
Adverse events (AEs)b, n (%)
Any AEc 39 (36.8) 88 (41.7) 85 (39.2)
Any serious 1 (0.9) 2 (0.9) 5 (2.3)
Any resulting in study discontinuation 1 (0.9) 3 (1.4) 5 (2.3)
Any severe grade 4 (3.8) 15 (7.1) 11 (5.1)
Any treatment-related AEd 4 (3.8) 41 (19.4) 42 (19.4)
Any resulting in study discontinuation 0 (0) 3 (1.4) 3 (1.4)
Application site reactions (ASRs), n (%)
Any ASRc 4 (3.8) 39 (18.5) 38 (17.5)
Any severe 1 (0.9) 9 (4.3) 6 (2.8)
Treatment-related AEs in >1% women for imiquimod 3.75% that were
more frequent than in placebo, n (%)b,d
Application site pain 0 (0) 11 (5.2) 17 (7.8)
Application site irritation 1 (0.9) 11 (5.2) 12 (5.5)
Application site pruritus 2 (1.9) 14 (6.6) 7 (3.2)
Application site bleeding 1 (0.9) 1 (0.5) 3 (1.4)
Application site discharge 0 (0) 1 (0.5) 3 (1.4)
Application site erythema 0 (0) 3 (1.4) 3 (1.4)
Rest periods
At least 1 rest period, n (%) 3 (2.8) 70 (33.2) 77 (35.5)
Dosing days missed due to rest, mean days (standard deviation)e 6.7 (4.7) 9.1 (7.2) 8.9 (7.2)
aOne woman assigned to imiquimod 2.5% received 3.75%. Displayed here based on treatment received.
bAdverse events reported from start of treatment to 30 days after study.
cBy preferred terms, regardless of causality assessment.
dInvestigator assessed causality of related or probably related.
eFor those women who took a rest.
Table 4: Summary of local skin reactions, maximum intensity during evaluation period.
Placebo Imiquimod 2.5% Imiquimod 3.75%
Women 105a 193a 203a
Local skin reaction (LSR), n (%)
Any LSR grade other than none 35 (33.3) 135 (69.9) 156 (76.8)
Severe grade
Any 1 (1.0) 26 (13.5) 36 (17.7)
Erythema 0 (0) 18 (9.3) 20 (9.9)
Edema 0 (0) 5 (2.6) 4 (2.0)
Weeping/exudates 0 (0) 1 (0.5) 2 (1.0)
Flaking/scaling/dryness 0 (0) 2 (1.0) 0 (0)
Scabbing/crusting 0 (0) 0 (0) 1 (0.5)
Erosion/ulceration 1 (1.0) 17 (8.8) 26 (12.8)
aDenominator is the number of women with at least 1 postbaseline assessment.
in these studies were higher than those observed in men in
the same studies (18.6% ITT and 22.7% PP for imiquimod
3.75%) [19, 22]. This gender diﬀerence is consistent with
prior experience with other therapies for EGWs, including
imiquimod [12], sinecatechins [23], podophyllin, cryother-
apy, and electrodessication [24]. Anatomic site-speciﬁc anal-
yses in women suggest that areas with more mucosal skin
(e.g., perianal areas) versus areas with more fully keratinized
skin (inguinal areas) may experience better eﬃcacy. This
observation, however, is limited in that the women were notInfectious Diseases in Obstetrics and Gynecology 9
randomized based on anatomic site involvement, and other
factors may be involved, such as disease severity within the
anatomic site or occlusion of the skin in certain areas.
Forwomenintheimiquimod3.75%groupwhoachieved
complete clearance, 65.3% of these women sustained clear-
ance during 12 weeks of observational follow-up. Sustained
complete clearance rate is a higher standard than recurrence
rate, which is sometimes reported. The former is what
patients desire, sustained freedom from warts, while the
latter may ignore untreated or new warts in the treatment
area and is inﬂuenced by the lost to follow-up rate. A high
sustainedcompleteclearancerateisconsistentwithimmune-
mediated clearance induced by imiquimod and was also seen
intheplacebogroupwherecompleteclearancewaslikelydue
to natural development of a robust cell-mediated immune
response. As very few placebo women achieved complete
clearance, however, this high sustained complete clearance
rate has limited clinical relevance.
The complete clearance rate observed with imiquimod
3.75% cream was lower than that reported by Edwards et
al. in 1998 for women treated with imiquimod 5% cream
applied 3x/week for up to 16 weeks [12]. However, there are
signiﬁcantlimitationsinmakingdirectcomparisonsbetween
the studies, because of diﬀerences in study designs, eﬃcacy
assessments, and enrolled populations. For example, in the
imiquimod 5% study, biopsy conﬁrmation was required at
entry. In the current studies, biopsies were not required to
be consistent with actual clinical practice; this may have
diluted observed eﬃcacy if women with conditions other
than EGWs were treated. Also, biopsy itself might cause
suﬃcient inﬂammation in some participants to activate the
cellular immune response, confounding the results.
In the imiquimod 5% study, not all anogenital regions
with warts were required to be treated (nontarget), and
new warts arising during study were not included in the
analyses [12]. Thus a participant could be categorized as
havingachievedinitial“completeclearance”,aswellashaving
“sustained complete clearance”, even if baseline “nontarget”
or “new” warts were present. In contrast, to achieve initial
complete clearance or have sustained complete clearance
in the current studies, a woman had to have no EGWs,
baseline or new, treated or untreated, in all of the anogenital
areas.Thisisconsistentwithcurrentregulatoryrequirements
for EGWs treatments, as well as reﬂective of real life, as
patients likely treat all of their warts and do not distinguish
between baseline versus newly emerged warts in evaluating
treatmentsuccess.Eﬃcacymayalsohavebeenaﬀectedbythe
unexpectedly long duration of disease in the current studies,
with ∼70% of women having EGWs >6 months and most
for more than a year. Longer duration of EGWs is associated
with lower treatment clearance rates [25]. This may reﬂect,
in part, selection for patients whose immune responses were
inadequate to clear the warts on their own.
Comparisons of the safety of imiquimod 3.75% with 5%
may similarly be impacted by diﬀerences between the study
designs, including usage of diﬀerent AE coding systems due
to changes in regulatory requirements. For the AEs reported
by the most subjects, the incidences were generally compa-
rable or lower for imiquimod 3.75% than for imiquimod
5% [21]. For example, the reported rates for application
site pain were similar (∼8%) in women, while the rates for
application site irritation/burning (5.5% versus 26%) and
application site pruritus/itching (3.2% versus 32%) were
lower for imiquimod 3.75% compared to imiquimod 5%.
There was a slightly higher overall rate of discontinuations
due to lost to follow-up in these studies as compared to
the imiquimod 5% study [12]. The imiquimod 5% study,
however, allowed for replacement of subjects discontinuing
for nonsafety reasons, which may have reduced the overall
discontinuation rate and the lost to follow-up rate. The
similar proportions of women lost to follow-up within each
treatment group in current studies, however, suggest these
discontinuations were unlikely to be due to AEs or treatment
failure. The lost to follow-up rates in the current studies,
mostly immediately after the baseline visit, may reﬂect
that EGWs are a sexually transmitted disease that tends to
aﬀect a younger, more mobile, and less compliant patient
population. This highlights one of the major challenges of
treatment in actual practice and emphasizes the importance
ofpractitionercommunicationwiththepatienttoencourage
follow-up. The PP results in these studies may be more
predictive than the ITT results of experience in clinical
settings where patients are routinely receiving medical care,
and therefore more likely to be adherent with treatment and
follow-up. Direct comparative clinical studies of imiquimod
3.75% versus other treatment options for EGWs using the
same endpoint of complete clearance of all EGWs, as well as
safety assessments, may be helpful to assess relative eﬃcacy
and safety.
In conclusion, in a combined analysis in women treating
EGWs for up to 8 weeks with imiquimod 2.5% and 3.75%
creams applied daily, both imiquimod products were well
tolerated and superior to placebo in completely clearing
all baseline and newly emergent warts, as well as reducing
wart counts compared to baseline. Imiquimod 3.75% cream,
however, was also superior to 2.5% with respect to reducing
wart counts and was the only product consistently superior
to placebo in the analyses of the individual studies. The
incremental eﬃcacy of imiquimod 3.75% did not appear to
be accompanied by an increase in intolerance. In women,
the observed anatomic site-speciﬁc clearance rates were
highestwithimiquimod3.75%creamintreatingwartsinthe
perinealandperianalareas.Imiquimod3.75%creamapplied
daily is an EGW treatment option that may be more intuitive
and reduce overall treatment duration for some women.
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